Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective

Drugs(2021)10.1007/s40265-021-01601-2Source: DataRank Database

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective is a research paper published in Drugs (2021). On theSindex it has a DataRank of 0.677. It has been cited 90 times.

N/A

0.677DataRank · unranked

Scored on demand from live citation data

90 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 4.40)OA: hybridTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.677

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (5)

Sean Barry,Ingrid Bourges,Panagiota Tsantili,Elena Wolff-Holz,Pekka Kurki ORCID

Live enrichment

PubMed:34596876 PMC:PMC8578115 OpenAlex:https://openalex.org/W3204021568

University of Helsinki including Helsinki University Central Hospital

FWCI

4.40

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40265-021-01601-2.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40265-021-01601-2.pdf

publisherhttps://link.springer.com/article/10.1007/s40265-021-01601-2/fulltext.html

journalhttps://doi.org/10.1007/s40265-021-01601-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34596876

Fields of Study

Biosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies ResearchStatistical Methods in Clinical Trials

MeSH Terms

Antibodies, MonoclonalDrug and Narcotic ControlEuropean UnionHumansImmunologic FactorsProduct Surveillance, PostmarketingTherapeutic EquivalencyAdverse Drug Reaction Reporting SystemsDrug ApprovalDrug SubstitutionBiosimilar Pharmaceuticals

Keywords

BiosimilarInterchangeabilityMedicinePharmacovigilanceAdverse effectPostmarketing surveillanceDiscontinuationImmunogenicityEuropean unionPharmacologyIntensive care medicineImmunologyBusinessSurgeryInternal medicineImmune system

Sustainable Development Goals

SDG 0: Good health and well-being

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective

FAIR Checklist

DataRank Breakdown

Authors (5)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)